Rolipram ZK 62711 the output signal beaches pHER2 determination, and the output signal N, the concentration of pertuzumab in PACT shown. 2B. The difference between the output signals from the INH Determined pensions properties of the dose-response of the STS. The inhibition of the HER2 receptor by 100 nM pertuzumab is responsible for 90% inhibition of the RTK pHER2 and 80% inhibition of PACT. To model the HER2 overexpression, we have ht 10 times the concentration of HER2 increased. Note that the original report HER2/HER3 the model equal to 1.4, which is PE04 close to a recent experimental measurement of the cell line. HER2 overexpression leads to an offset in the totally Imatinib Glivec independent Ngig pHER2 dose for PAKT and pertuzumab in h Higher concentrations. This effect leads to an increase of about 200 times for PACT IC50 and EC50 pHER2, and the 50% inhibition causes an inhibition of 10% of the PACT pHER2. These results show that the overexpression of HER2 causes insensitivity of the SSR and the SN than for pertuzumab in the physiological range of concentrations of pertuzumab. In order to study the responses to pHER2 PACT and pertuzumab in a wide range of expression of HER2, we calculated dose dependence Dependencies pHER2 PACT for HER2 and concentration in the presence and absence of 100 nM pertuzumab.
A HER2100 nM SN and the RSS work in the south Saturation in the absence of S Saturation and is not in the presence of pertuzumab pertuzumab. With an increase of HER2 CCI-779 mTOR inhibitor overexpression by two JOB GE ofmagnitude, RSS and SN return to the city He work in the south Saturation in the presence of 100 nM pertuzumab. Note that in our model, we do not take into account the ligand-independent Independent HER2 HER2 activation by homodimerization with overexpression of HER2, and focus on HER2/HER3 activation of PI3K / PTEN / AKT. Accordingly, we propose that a 10-fold HER2 not changed The kinetics of receptor heterodimerization HER2/HER3 and R HER2 homodimerization in AKT activation is negligible. Our calculation refers to the case of a lower level of HER2 overexpression occurs in the transcription / translationalmechanisms without gene amplification. An extension of our model is necessary to describe and explained Utern the effects of the ligand-independent Independent activation of HER2 resistance to Vinflunine trastuzumab and pertuzumab and abnormal phosphorylation of HER2 in the action of trastuzumab and pertuzumab in HER2 amplification. To analyze the sensitivity of the flow pertuzumab, we compared the sensitivities RSS for initial concentrations of receptors and their kinetic parameters, SRSS, i, in the absence and presence of 100 nM pertuzumab.
As shown in Fig. 3, caused a significant pertuzumab erh Increase the sensitivity pHER2, SRSS, i, at initial concentrations of HRG and HER2 as well as almost all the kinetic parameters k SSR in comparison to the sensitivity pHER2 without pertuzumab. This effect results from the membrane transition from kinetic RSS S Saturation S Saturation mode is not due to inhibition of HER2 by pertuzumab. In S Saturation is not the Internet. RSS becomesmore sensitive to the concentration of HER2 and kinetic properties of the receptors in the S Saturation mode transition to the S Saturation in non-S Ttigungsmodus due to increased Hten concentration of HER2 by the degradation was pHER2 sensitivities given, SRSS, i, pertuzumab action . Thus, the suppression of pertuzu.